Creative Medical Technology Holdings to Launch StemSpine in the United States

Creative Medical Technology Holdings Inc., a leading commercial stage biotechnology company focused on urology, neurology and orthopedics using stem cell treatments, has announced the successful clinical commercialization of StemSpine®.
 
StemSpine, a patented procedure for the treatment of chronic lower back pain (CLBP) utilizing a patient’s own stem cells, has successfully been implemented with the treatment of the first patients with more than 12 months of data showing safety and efficacy. The company plans to submit the results for publication in a peer reviewed journal imminently.

The company will begin commercializing StemSpine in the United States with the launch of a new website and physician recruitment in the weeks ahead. “As we’ve previously announced it was our goal to commercialize StemSpine in 2019, so we’re pleased with the progress of this technology and the value it brings to our company as domestic commercialization begins,” said Timothy Warbington, president and CEO of Creative Medical Technology Holdings Inc.
 
“StemSpine will surely be welcomed by the over 50 million Americans suffering from CLBP in the United States as a drug free alternative. Currently, there are minimal treatment options for patients that suffer from this debilitating pain, with roughly 50 percent of patients progressing to opioids and surgery,”¹ said Thomas Ichim Ph.D., chief scientific officer of Creative Medical Technology Holdings Inc. and patent inventor.

Chronic lower back pain represents a leading cause of disability worldwide and is the most common non-cancer reason for opioid prescription in the United States. It affects up to 30 percent of U.S. adults and is estimated to cost the U.S. healthcare system more than $100 billion each year.
 
Reference
¹ https://healthcare.utah.edu/publicaffairs/news/2019/10/heal-initiative.php